The global market for hyperphosphatemia treatment is expected to be valued at around USD 12.66 Billion in 2023 and is projected to expand at a CAGR of over 4.8% through 2033. The market is expected to surpass a staggering value of USD 20.24 Billion by 2033.
In chronic kidney disease, hyperphosphatemia affects 70% of people. In a unanimous vote (9 to 4) for the use of Tenapanor (Xphozah®) as monotherapy in adult patients who are undergoing dialysis for controlling serum phosphorus, as well as in combination with phosphate binders (10 to 2, with one abstention), the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee approved Tenapanor (Xphozah®) monotherapy.
The condition of hyperphosphatemia can have a significant impact on soft tissue and cardiovascular calcification. In order to improve patient’s quality of life and longevity, the National Kidney Foundation's Kidney Disease Outcome Quality Initiative (K/DOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend stricter levels of serum phosphorus and calcium-phosphate product control.
Research in recent years has greatly contributed to improving the understanding of ESRD patients with hyperphosphatemia's pathophysiology. Patients on hemodialysis who have hyperphosphatemia may experience a significant reduction in mortality rates associated with cardiac disease if they receive appropriate and continuous education about the use of their medications.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | USD 10.1 Billion |
| Expected Market Value (2023) | USD 12.66 Billion |
| Projected Forecast Value (2033) | USD 20.24 Billion |
| Global Growth Rate (2023 to 2033) | 4.8% CAGR |
According to Fact.MR, hyperphosphatemia sales grew at a CAGR of 4% in the historical period 2018 to 2022. During the forecast period, the demand for emerging therapies will also be fueled by the expected launch of novel treatments and pharmaceutical companies' research and development activities. Proactively pursuing reimbursement during late development and after launch can have a beneficial effect.
Phosphate-binder treatment has made recent advances. As a result of hypercalcemia, sevelamer, and lanthanum are effective in the prevention of cardiovascular mortality. Some patients may benefit from the newly approved iron-based products, but there's no data on long-term safety. For pharmacists to optimize hyperphosphatemia therapy, knowing these new treatments is crucial as essential members of the care team.
Globally, chronic kidney diseases are becoming more prevalent, resulting in significant growth in new drug development and therapeutics. In recent years, new therapies have been conceptualized based on new mechanistic understandings of phosphorus absorption. Accordingly, the market for hyperphosphatemia treatment is projected to grow at a CAGR of 4.8% between 2023 and 2033.
A Growing Number of Health Conditions will drive Hyperphosphatemia Market Demand
The growing prevalence of chronic diseases and the growing geriatric population are expected to drive the market demand for hyperphosphatemia treatments. As Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) patients become more prevalent, the market will witness a surge in investment and development of newer mechanisms of action.
As the FDA and other government funding bodies continue to grow in the coming years, it is expected that the market will continue to grow. With the increase in Research and Development funding and the development of biotechnology advancements and studies, the market for hyperphosphatemia is expected to grow in the upcoming years. The market for hyperphosphatemia diagnosis and drug treatments is expected to grow further due to the growing number of anemic women in emerging countries and anemic conditions in children.
Insights into the Future of Hyperphosphatemia Markets
Researchers have investigated a number of hyperphosphatemia treatment approaches to reduce its burden. Various treatments for hyperphosphatemia that lower phosphate levels have been demonstrated to be successful in controlling and preventing hyperphosphatemia through the use of these strategies.
With the launch of more drugs in developing economies, the hyperphosphatemia treatment market is expected to witness significant growth in the near future. For instance, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) revealed that Velphoro (PA21) lowered serum phosphorus in CKD dialysis patients in April 2021.
Furthermore, studies also showed using Raman spectroscopy and attenuated total reflectance Fourier transform infrared spectroscopy, the researchers confirmed the formation of noncovalent hydrogen bonds in the hetero synthon. For instance, Sanofi-Aventis Korea announced in March that it had entered into a joint marketing and sales agreement with Handok for the latter's hyperphosphatemia treatment Renvela.
Phosphate levels that are too high can cause serious health conditions if left untreated. Among them are diabetes and kidney disease. A treatment program may be needed to prevent this condition from developing. The market for hyperphosphatemia is expected to grow at a brisk pace, but there are a few factors that may hinder its growth, including a poor understanding of what phosphate levels are in food products and the lack of data on how phosphates are managed, a significant cost, and increased competition within the industry make it difficult to manage them.
Moreover, the stricter regulations imposed by the regulatory agencies will further impede the sales of hyperphosphatemia drugs, which will further dampen the demand for these drugs. A rise in side effects associated with drugs and the high cost of diagnosis is expected to hamper the growth of this industry.
New Entrants Lead to Improvement in Hyperphosphatemia
With technological advancements in the hyperphosphatemia field, new companies are entering the market and gaining a competitive edge. In order to stay ahead of changing consumer preferences, these companies continually invest in research and development. By advancing the market, the company aims to improve its position in the hyperphosphatemia market.
Shield Therapeutics: Pharmaceutical company that develops products to treat iron deficiency anemia and hyperphosphatemia. The company's lead product is Feraccru, an oral therapy that is stable and non-salt-based to treat iron deficiency in adults. Aside from PT20, the company also has PT30 to provide hypoallergenic IV iron therapy, and PT40 to make a generic version of iron sucrose, which may be used to treat patients with hyperphosphatemia due to dialysis or chronic kidney disease.
Alebund: Manufacturer of kidney therapeutics. Lead candidates include AP-301 which is being evaluated for the treatment of hyperphosphatemia, AP-303, which is for the treatment of diabetic kidney disease, AP-304, which is being evaluated for the treatment of autosomal dominant polycystic kidney disease, and AP-305, which is an antibody against the enzyme in the complement system lectin pathway for the treatment of IgA nephropathy.
Llypsa: Develops compounds to bind phosphates and potassium for the treatment of chronic kidney diseases. One of the company’s lead drug candidates, ILY101, prevents hyperphosphatemia, a condition characterized by high levels of phosphorus in the blood. A phosphorus-binding compound, ILY101, prevents the body from absorbing phosphorus. As well as potassium and sodium binders, Ilypsa has other candidates in its pipeline.
Increased Advances in Drugs, along with Investments to propel Market Expansion
According to the forecast, North American sales will account for 36% of the overall demand in the forthcoming decade. In North America, hyperphosphatemia diagnosis investments are rising, which will lead to market dominance. Health awareness and the availability of modern diagnostic facilities have made the United States the dominant market in North America.
North America is by far the global market leader in terms of medications for hyperphosphatemia, both in terms of income and in terms of the number of patients. Among the North American population, hyperphosphatemia therapeutics are growing at an accelerating rate as diabetes, osteoporosis, and a variety of chronic renal diseases are on the rise. Chronic kidney disease (CKD) affects about 15% of American adults, and 1 in 3 are at risk. There are approximately 560,000 dialysis patients in the United States. The burden of chronic kidney disease and end-stage renal disease is disproportionately higher for minorities; the likelihood that Black Americans require dialysis is 4 times higher than that of White Americans.
Moreover, the rising prevalence of hyperphosphatemia as well as the development of osteoporosis and a variety of chronic kidney diseases are driving the growth of the market for hyperphosphatemia therapeutic drugs in North America. A recent study by Block et al concluded that despite attempts made by patients, dietitians, and nephrologists to reach 5.5 mg/dL as the recommended goal for serum phosphorus, approximately 60% of American patients on hemodialysis have phosphorus levels above this goal.
Pharmaceuticals will Dominate the Emerging Markets Hyperphosphatemia Market
Estimates indicate that Asia Pacific will dominate the global market. Globally, this region generates 32% of the revenues generated worldwide, making up a substantial portion of global revenues. Asia-Pacific is experiencing the fastest market growth. In the Asia-Pacific region, China is expected to be the biggest market, both in revenue and size. With China's central government's robust growth initiatives, it is expected that the country's healthcare infrastructure will increase the demand for hyperphosphatemia medications.
As the FDA approves more of these drugs, and dialysis services increase in major countries, phosphate binders in the region are in greater demand. Emerging countries, such as China, India, and Brazil, are distinguished from developed countries by the prevalence of calcium-based phosphate binders in prescriptions, and the significant increase in dialysis patients in Asia Pacific, as well as a significant increase in the number of dialysis patients, are expected to boost demand during the period 2023 to 2033.
Due to the increasing aging population, the increasing osteoporosis cases, and changes in dietary habits, the Asia-Pacific market is set to grow at an increasing rate. Hyperphosphatemia drugs are being increasingly used in Asia-Pacific as a consequence of the increasing number of osteoporosis cases and this is the biggest factor driving the market for these drugs.
Iron Based Phosphate Binder Growth will be Fueled by New Clinical Trials
Based on drug class the market is segmented into calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and non-phosphate binders. According to Future Market Insights, iron-based phosphate binders will continue to dominate the market throughout the forecast period. Approximately 20% of all medical treatments are based on iron-based phosphate binders.
New classes of phosphate binders are based on iron. Clinical trials have been conducted on various iron-based phosphate binders. Two iron-based binders have been approved for clinical use in the United States after being found to be safe and effective in lowering serum phosphate levels: ferric citrate (JTT-751) and sucroferric oxyhydroxide (PA21). In comparison to sucroferric oxyhydroxide, ferric citrate absorbs iron partially.
In order to grow the market for hyperphosphatemia in dialysis patients, growing awareness about phosphorus levels is expected to drive the market. For instance, a new study has found that ferric citrate improved biomarkers of hyperphosphatemia and anemia in patients treated with ferric citrate after clinical trials have granted approval. In comparison with calcium-based binders or sevelamer salts, both of these agents are effective in reducing serum phosphorus levels. A number of factors need to be explored in order to determine their optimal place in therapy, including pill burden, adverse effects on the gastrointestinal system, potential cost reduction strategies for anemia therapies, and the physiological effects of long-term exposure to iron.
The low serum calcium level test is expected to represent 8% of the market at the end of the evaluation period with a CAGR of 3% during the forecast period. As the population ages and calcium levels decrease, the market for low serum calcium level tests is expected to grow as a result of this. Low serum calcium level tests will continue to grow in the market as an increasing number of pregnant women, as well as an increase in bone diseases, is expected to increase market demand for low serum calcium level tests.
A growing number of home-based tests and a growing demand for at-home test kits in the market is expected to lead to a growth in the low serum calcium level test market next year. In addition to this, the growing prevalence of kidney disease and thyroid disease is expected to further contribute to the growth of the market for low serum calcium level tests. As industry advancements continue to grow and more and more customers demand quick test results and more accurate devices, the market is expected to continue growing.
Several domestic and regional players are involved in the hyperphosphatemia market, which is highly fragmented and competitive. Hyperphosphatemia's major market players are investing in Research and Development to learn more about treatment options and determine their accuracy.
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: APAC Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: APAC Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Table 24: APAC Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 27: MEA Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Table 28: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Test Type, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Test Type, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Market Attractiveness by Test Type, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Test Type, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Test Type, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Market Attractiveness by Test Type, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Test Type, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Test Type, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Test Type, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Test Type, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Test Type, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Test Type, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Test Type, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Test Type, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Test Type, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: APAC Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: APAC Market Value (US$ Million) by Test Type, 2023 to 2033
Figure 103: APAC Market Value (US$ Million) by End User, 2023 to 2033
Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: APAC Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 109: APAC Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: APAC Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: APAC Market Value (US$ Million) Analysis by Test Type, 2018 to 2033
Figure 112: APAC Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033
Figure 113: APAC Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033
Figure 114: APAC Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: APAC Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: APAC Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: APAC Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: APAC Market Attractiveness by Test Type, 2023 to 2033
Figure 119: APAC Market Attractiveness by End User, 2023 to 2033
Figure 120: APAC Market Attractiveness by Country, 2023 to 2033
Figure 121: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 122: MEA Market Value (US$ Million) by Test Type, 2023 to 2033
Figure 123: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 129: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 131: MEA Market Value (US$ Million) Analysis by Test Type, 2018 to 2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033
Figure 134: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 137: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 138: MEA Market Attractiveness by Test Type, 2023 to 2033
Figure 139: MEA Market Attractiveness by End User, 2023 to 2033
Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
The hyperphosphatemia treatment market was valued at USD 12.1 Billion in 2022
According to Fact.MR, the hyperphosphatemia market is expected to reach USD 12.66 billion by 2023.
From 2023 to 2033, Fact.MR expects hyperphosphatemia revenue to flourish at a 4.8% CAGR
The hyperphosphatemia market is expected to reach USD 20.24 Billion by 2033
The North American market is expected to account for more than 36% of industry revenues in 2023.
Europe's hyperphosphatemia market share is expected to increase to 25% by 2033.
Ardelyx, Shield Therapeutics, Sanofi, Takeda Pharmaceutical Company, and Astellas Pharma Inc. are the top 5 market players in the hyperphosphatemia market.
Market share for hyperphosphatemia in Asia Pacific is forecast to reach 32% by 2033.
Hyperphosphatemia in iron-based phosphate binders will account for 20% of the market by 2023.
Hyperphosphatemia Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
